Cargando…
Successful treatment of advanced ovarian cancer with anlotinib: a case report
Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724413/ https://www.ncbi.nlm.nih.gov/pubmed/33284728 http://dx.doi.org/10.1177/0300060520976824 |
_version_ | 1783620531018268672 |
---|---|
author | Zhang, Ping Ma, Liangliang Wang, Xiaojie Zhang, Ruijie Dong, Yuting |
author_facet | Zhang, Ping Ma, Liangliang Wang, Xiaojie Zhang, Ruijie Dong, Yuting |
author_sort | Zhang, Ping |
collection | PubMed |
description | Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated clinical antitumor activity of anlotinib in various cancers. We report the case of an elderly woman with advanced ovarian cancer who received anlotinib after failure of multiple-line chemotherapy. A partial response was observed after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She continued to take anlotinib, with a progression-free survival time of more than 4 months. Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a novel therapeutic option for patients with advanced ovarian cancer. |
format | Online Article Text |
id | pubmed-7724413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77244132020-12-16 Successful treatment of advanced ovarian cancer with anlotinib: a case report Zhang, Ping Ma, Liangliang Wang, Xiaojie Zhang, Ruijie Dong, Yuting J Int Med Res Case Report Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated clinical antitumor activity of anlotinib in various cancers. We report the case of an elderly woman with advanced ovarian cancer who received anlotinib after failure of multiple-line chemotherapy. A partial response was observed after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She continued to take anlotinib, with a progression-free survival time of more than 4 months. Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a novel therapeutic option for patients with advanced ovarian cancer. SAGE Publications 2020-12-07 /pmc/articles/PMC7724413/ /pubmed/33284728 http://dx.doi.org/10.1177/0300060520976824 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Zhang, Ping Ma, Liangliang Wang, Xiaojie Zhang, Ruijie Dong, Yuting Successful treatment of advanced ovarian cancer with anlotinib: a case report |
title | Successful treatment of advanced ovarian cancer with anlotinib: a case
report |
title_full | Successful treatment of advanced ovarian cancer with anlotinib: a case
report |
title_fullStr | Successful treatment of advanced ovarian cancer with anlotinib: a case
report |
title_full_unstemmed | Successful treatment of advanced ovarian cancer with anlotinib: a case
report |
title_short | Successful treatment of advanced ovarian cancer with anlotinib: a case
report |
title_sort | successful treatment of advanced ovarian cancer with anlotinib: a case
report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724413/ https://www.ncbi.nlm.nih.gov/pubmed/33284728 http://dx.doi.org/10.1177/0300060520976824 |
work_keys_str_mv | AT zhangping successfultreatmentofadvancedovariancancerwithanlotinibacasereport AT maliangliang successfultreatmentofadvancedovariancancerwithanlotinibacasereport AT wangxiaojie successfultreatmentofadvancedovariancancerwithanlotinibacasereport AT zhangruijie successfultreatmentofadvancedovariancancerwithanlotinibacasereport AT dongyuting successfultreatmentofadvancedovariancancerwithanlotinibacasereport |